1
|
Petrovic D, Bankir L, Ponte B, Pruijm M, Corre T, Ghobril JP, Bouatou Y, Ackermann D, Vogt B, Bochud M. The urine-to-plasma urea concentration ratio is associated with eGFR and eGFR decline over time in a population cohort. Nephrol Dial Transplant 2023; 39:122-132. [PMID: 37381173 PMCID: PMC10730796 DOI: 10.1093/ndt/gfad131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Indexed: 06/30/2023] Open
Abstract
BACKGROUND Evaluation of renal function and of factors associated with its decline are important public health issues. Besides markers of glomerular function [e.g. glomerular filtration rate (GFR)], those of tubular functions are rarely evaluated. Urea, the most abundant urinary solute, is markedly concentrated in urine when compared with plasma. We explored the urine-to-plasma ratio of urea concentrations (U/P urea ratio) as a marker of tubular functions. METHODS We evaluated the relationship of the U/P urea ratio with eGFR at baseline in 1043 participants (48 ± 17 years) from the Swiss Kidney Project on Genes in Hypertension (SKIPOGH) population-based cohort, using mixed regression. In 898 participants, we assessed the relation between U/P urea ratio and renal function decline between two study waves 3 years apart. We studied U/P ratios for osmolarity, Na, K and uric acid for comparison. RESULTS In a transversal study at baseline, estimated GFR (eGFR) was positively associated with U/P-urea ratio [βscaled = 0.08, 95% CI (0.04; 0.13)] but not with the U/P ratio of osmolarity. Considering separately participants with renal function >90 or ≤90 mL/min × 1.73 m2, this association was observed only in those with reduced renal function. In the longitudinal study, eGFR declined at a mean rate of 1.2 mL/min per year. A significant association was observed between baseline U/P urea ratio and eGFR decline [βscaled = 0.08, 95% CI (0.01; 0.15)]. A lower baseline U/P urea ratio was associated with a greater eGFR decline. CONCLUSION This study provides evidence that the U/P urea ratio is an early marker of kidney function decline in the general adult population. Urea is easy to measure with well-standardized techniques and at low cost. Thus, the U/P urea ratio could become an easily available tubular marker for evaluating renal function decline.
Collapse
Affiliation(s)
- Dusan Petrovic
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
- Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | - Lise Bankir
- Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université de Paris, Paris, France
- CNRS, ERL 8228 – Laboratoire de Physiologie Rénale et Tubulopathies, Paris, France
| | - Belén Ponte
- Department of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland
| | - Menno Pruijm
- Department of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Tanguy Corre
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
| | - Jean-Pierre Ghobril
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
| | - Yassine Bouatou
- Department of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland
| | - Daniel Ackermann
- Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Bruno Vogt
- Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Murielle Bochud
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
| |
Collapse
|
2
|
Kaiser C, Aeberli J, Ponte B. [HTA and PTSD: mechanisms and clinical implications]. Rev Med Suisse 2023; 19:1668-1673. [PMID: 37702470 DOI: 10.53738/revmed.2023.19.841.1668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/14/2023]
Abstract
The causes of arterial hypertension are numerous, but the environment can be a contributing factor. Stress is one of these environmental factors that is difficult to assess. We focus on Post-Traumatic Stress Disorder (PTSD), which is often under-diagnosed and under-recognised in diagnostic and therapeutic strategies. We specifically look at the psychosomatic implications of stress, which put patients with PTSD at a higher risk of developing HTA, and we suggest some therapeutic approaches. Early screening and diagnosis are essential to reduce this major cardiovascular risk factor.
Collapse
Affiliation(s)
- Céline Kaiser
- Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Julia Aeberli
- Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Belén Ponte
- Service de néphrologie et hypertension, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
3
|
Gressot G, Huegli S, Wilhelm-Bals A, Ponte B. [Solitary kidney: a risk factor for hypertension]. Rev Med Suisse 2023; 19:1651-1655. [PMID: 37702467 DOI: 10.53738/revmed.2023.19.841.1651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/14/2023]
Abstract
In patients with solitary kidney, either congenital or acquired, compensatory mechanisms come into play to maintain renal function, such as glomerular hyperfiltration and hypertrophy and renin-angiotensin-aldosterone system activation. In the long term, these mechanisms lead to arterial hypertension and then chronic kidney disease. The risk of arterial hypertension is greater in cases of congenital single kidney or of nephrectomy in childhood than in adulthood. Having a single kidney increases the risk of gestational hypertension and pre-eclampsia. Antihypertensive treatment is based on Angiotensin-converting enzyme inhibitors and sartans for their anti-proteinuric effect but otherwise does not differ from that of the general population.
Collapse
Affiliation(s)
| | - Sophie Huegli
- Service de néphrologie et hypertension artérielle, Hôpitaux universitaires de Genève, 1211 Genève 14
| | | | - Belén Ponte
- Service de néphrologie et hypertension artérielle, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
4
|
Visconti G, de Figueiredo M, Strassel O, Boccard J, Vuilleumier N, Jaques D, Ponte B, Rudaz S. Multitargeted Internal Calibration for the Quantification of Chronic Kidney Disease-Related Endogenous Metabolites Using Liquid Chromatography-Mass Spectrometry. Anal Chem 2023; 95:13546-13554. [PMID: 37655548 PMCID: PMC10500547 DOI: 10.1021/acs.analchem.3c02069] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 08/16/2023] [Indexed: 09/02/2023]
Abstract
Accurate quantitative analysis in liquid chromatography-mass spectrometry (LC-MS) benefits from calibration curves generated in the same matrix as the study sample. In the case of endogenous compound quantification, as no blank matrix exists, the multitargeted internal calibration (MTIC) is an attractive and straightforward approach to avoid the need for extensive matrix similarity evaluation. Its principle is to take advantage of stable isotope labeled (SIL) standards as internal calibrants to simultaneously quantify authentic analytes using a within sample calibration. An MTIC workflow was developed for the simultaneous quantification of metabolites related to chronic kidney disease (CKD) using a volumetric microsampling device to collect 20 μL of serum or plasma, followed by a single-step extraction with acetonitrile/water and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Since a single concentration of internal calibrant is necessary to calculate the study sample concentration, the instrument response function was investigated to determine the best SIL concentration. After validation, the trueness of 16 endogenous analytes in authentic human serum ranged from 72.2 to 116.0%, the repeatability from 1.9 to 11.3%, and the intermediate precision ranged overall from 2.1 to 15.4%. The proposed approach was applied to plasma samples collected from healthy control participants and two patient groups diagnosed with CKD. Results confirmed substantial concentration differences between groups for several analytes, including indoxyl sulfate and cortisone, as well as metabolite enrichment in the kynurenine and indole pathways. Multitargeted methodologies represent a major step toward rapid and straightforward LC-MS/MS absolute quantification of endogenous biomarkers, which could change the paradigm of MS use in clinical laboratories.
Collapse
Affiliation(s)
- Gioele Visconti
- School
of Pharmaceutical Sciences, University of
Geneva, CMU −
Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
- Institute
of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU − Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
| | - Miguel de Figueiredo
- School
of Pharmaceutical Sciences, University of
Geneva, CMU −
Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
- Institute
of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU − Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
| | - Oriane Strassel
- School
of Pharmaceutical Sciences, University of
Geneva, CMU −
Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
- Institute
of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU − Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
| | - Julien Boccard
- School
of Pharmaceutical Sciences, University of
Geneva, CMU −
Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
- Institute
of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU − Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
| | - Nicolas Vuilleumier
- Department
of Genetic and Laboratory Medicine, Geneva
University Hospitals (HUG), Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland
| | - David Jaques
- Service
of Nephrology, Geneva University Hospitals
(HUG), Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Belén Ponte
- Service
of Nephrology, Geneva University Hospitals
(HUG), Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Serge Rudaz
- School
of Pharmaceutical Sciences, University of
Geneva, CMU −
Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
- Institute
of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU − Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
| |
Collapse
|
5
|
Jaques DA, Ponte B, Olivier V, de Seigneux S, Feraille E, Burnier M, Pechère-Bertschi A. Variability of 24-Hour Sodium Urinary Excretion in Young Healthy Males Based on Consecutive Urine Collections: Impact on Categorization of Salt Intake. J Ren Nutr 2023; 33:450-455. [PMID: 36738948 DOI: 10.1053/j.jrn.2022.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 11/17/2022] [Accepted: 12/19/2022] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVE Several nonconsecutive 24-h urinary collections are considered the gold standard for estimating dietary salt intake. As those samples are logistically demanding, we aimed to describe the variability of 24-h sodium urinary excretion over consecutive days and report its adequacy with sodium intake. METHODS We enrolled 16 healthy male volunteers in a prospective controlled study. All participants randomly received a low salt diet (LSD) (3 g/day of NaCl), a normal salt diet (NSD) (6 g/day of NaCl), and a high salt diet (HSD) (15 g/day of NaCl) for 7 days in a crossover design without wash-out period. RESULTS On day 6, median sodium urinary excretion was 258 (216-338), 10 (8-18), and 87 (69-121) mmol/day for HSD, LSD, and NSD, respectively (P < .001). When considering days 4-6, sodium urinary excretion was in steady state as models with and without interaction term "diet type X sample day" were not significantly different (P = .163). On day 6, area under the curve (AUC) of receiver operating characteristic for urinary sodium excretion to detect HSD was 1.0 (1.0-1.0) and a cut-point of 175 mmol/day was 100% sensitive and specific to detect HSD. On day 6, receiver operating characteristic AUC to detect LSD was 0.993 (0.978-1.0) and a cut-point of 53 mmol/day was 96.4% sensitive and 100% specific to detect LSD. CONCLUSION A steady state of sodium balance, where sodium intake is proportional to its excretion, is reached within a few days under a constant diet in the real-life setting. Categorization of salt consumption into low (3 g/day), normal (6 g/day), or high (15 g/day) based on a single 24-h urine collection is nearly perfect. Based on these results, repeated nonconsecutive urine collection might prove unnecessary to estimate sodium intake in daily clinical practice provided that diet is rather constant over time.
Collapse
Affiliation(s)
- David A Jaques
- Division of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland.
| | - Belén Ponte
- Division of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland
| | - Valérie Olivier
- Division of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland; Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland
| | - Sophie de Seigneux
- Division of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland; Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland
| | - Eric Feraille
- Division of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland; Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland
| | - Michel Burnier
- Division of Nephrology and Hypertension, Lausanne University Hospitals, Lausanne, Switzerland
| | | |
Collapse
|
6
|
Wuerzner G, Ponte B, Pechère-Bertschi A. [Hypertension: what's new in 2022]. Rev Med Suisse 2023; 19:221-224. [PMID: 36723652 DOI: 10.53738/revmed.2023.19.812.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Our article summarizing the most important studies of the past year emphasizes the difficulty of controlling blood pressure (BP) in hypertensive patients. In addition, it discusses factors such as temperature and sodium that may influence BP, proposes new targets in pregnant hypertensive patients, and challenges the usefulness of taking an antihypertensive drug nightly. Finally, a strategy targeting endothelin blockade in resistant hypertension is presented.
Collapse
Affiliation(s)
- Grégoire Wuerzner
- Service de néphrologie et hypertension, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Belén Ponte
- Service de néphrologie et hypertension, Hôpitaux universitaires de Genève, 1211 Genève 14
| | | |
Collapse
|
7
|
Petrovic D, Carmeli C, Sandoval JL, Bodinier B, Chadeau-Hyam M, Schrempft S, Ehret G, Dhayat NA, Ponte B, Pruijm M, Vineis P, Gonseth-Nusslé S, Guessous I, McCrory C, Bochud M, Stringhini S. Life-course socioeconomic factors are associated with markers of epigenetic aging in a population-based study. Psychoneuroendocrinology 2023; 147:105976. [PMID: 36417838 DOI: 10.1016/j.psyneuen.2022.105976] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 11/14/2022] [Accepted: 11/14/2022] [Indexed: 11/18/2022]
Abstract
Adverse socioeconomic circumstances negatively affect the functioning of biological systems, but the underlying mechanisms remain only partially understood. Here, we explore the associations between life-course socioeconomic factors and four markers of epigenetic aging in a population-based setting. We included 684 participants (52 % women, mean age 52.6 ± 15.5 years) from a population and family-based Swiss study. We used nine life-course socioeconomic indicators as the main exposure variables, and four blood-derived, second generation markers of epigenetic aging as the outcome variables (Levine's DNAmPhenoAge, DunedinPoAm38, GrimAge epigenetic age acceleration (EAA), and the mortality risk score (MS)). First, we investigated the associations between socioeconomic indicators and markers of epigenetic aging via mixed-effect linear regression models, adjusting for age, sex, participant's recruitment center, familial structure (random-effect covariate), seasonality of blood sampling, and technical covariates. Second, we implemented counterfactual mediation analysis to investigate life-course and intermediate mechanisms underlying the socioeconomic gradient in epigenetic aging. Effect-size estimates were assessed using regression coefficients and counterfactual mediation parameters, along with their respective 95 % confidence intervals. Individuals reporting a low father's occupation, adverse financial conditions in childhood, a low income, having financial difficulties, or experiencing unfavorable socioeconomic trajectories were epigenetically older and had a higher mortality risk score than their more advantaged counterparts. Specifically, this corresponded to an average increase of 1.1-1.5 years for Levine's epigenetic age (β and 95 %CI range, β (minimum and maximum): 1.1-1.5 95 %CI[0.0-0.2; 2.3-3.0]), 1.1-1.5 additional years for GrimAge (β: 1.1-1.5 95 %CI[0.2-0.6; 1.9-3.0]), a 1-3 % higher DunedinPoAm38 age acceleration (β: 0.01-0.03 95 %CI[0.00; 0.03-0.04]), and a 10-50 % higher MS score (β: 0.1-0.4 95 %CI[0.0-0.2; 0.3-0.4]) for the aforementioned socioeconomic indicators. By exploring the life-course mechanisms underlying the socioeconomic gradient in epigenetic aging, we found that both childhood and adulthood socioeconomic factors contributed to epigenetic aging, and that detrimental lifestyle factors mediated the relation between socioeconomic circumstances in adulthood and EAA (31-89 % mediated proportion). This study provides emerging evidence for an association between disadvantaged life-course socioeconomic circumstances and detrimental epigenetic aging patterns, supporting the "sensitive-period" life-course model. Counterfactual mediation analyses further indicated that the effect of socioeconomic factors in adulthood operates through detrimental lifestyle factors, whereas associations involving early-life socioeconomic factors were less clear.
Collapse
Affiliation(s)
- Dusan Petrovic
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland; Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
| | - Cristian Carmeli
- Population Health Laboratory, University of Fribourg, Fribourg, Switzerland
| | - José Luis Sandoval
- Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
| | - Barbara Bodinier
- Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | - Marc Chadeau-Hyam
- Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | - Stephanie Schrempft
- Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Georg Ehret
- Department of Cardiology, Geneva University Hospitals, Geneva, Switzerland
| | - Nasser Abdalla Dhayat
- Nephrology & Renal Care Center, B. Braun Medical Care AG, Hochfelden, Zurich, Switzerland
| | - Belén Ponte
- Department of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland
| | - Menno Pruijm
- Department of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Paolo Vineis
- Department of Medical Gerontology, Trinity College Dublin, Dublin, Ireland
| | - Sémira Gonseth-Nusslé
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
| | - Idris Guessous
- Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Cathal McCrory
- Department of Medical Gerontology, Trinity College Dublin, Dublin, Ireland
| | - Murielle Bochud
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
| | - Silvia Stringhini
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
8
|
Ghobril JP, Petrovic D, Ehret G, Ponte B, Pruijm M, Ackermann D, Vogt B, Stringhini S, Thomas A, Chamberlain J, Gonseth-Nusslé S, Bochud M. PhenoExplorer: An Interactive Web-based Platform for Exploring (Epi)Genome-Wide Associations Using a Swiss Population-based Study. Chimia (Aarau) 2022; 76:1052-1062. [PMID: 38069802 DOI: 10.2533/chimia.2022.1052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 10/31/2022] [Indexed: 12/18/2023] Open
Abstract
The recent advent of high-throughput sequencing technologies has allowed exploring the contribution of thousands of genomic, epigenomic, transcriptomic, or proteomic variants to complex phenotypic traits. Here, we sought to conduct large-scale (Epi)Genome-Wide Association Studies (GWAS/EWAS) to investigate the associations between genomic (Single Nucleotide Polymorphism; SNP) and epigenomic (Cytosine-Phospho-Guanine; CpG) markers, with multiple phenotypic traits in a population-based context. We used data from SKIPOGH, a family- and population-based cohort conducted in the cities of Lausanne, Geneva, and Bern (N=1100). We used 7,577,572 SNPs, 420,444 CpGs, and 825 phenotypes, including anthropometric, clinical, blood, urine, metabolite, and metal measures. GWAS analyses assessed the associations between SNPs and metabolites and metals (N=279), using regression models adjusted for age, sex, recruitment center, and familial structure, whereas EWAS analyses explored the relations between CpGs and 825 phenotypes, additionally adjusting for the seasonality of blood sampling and technical nuisance. Following the implementation of GWAS and EWAS analyses, we developed a web-based platform, PhenoExplorer, aimed at providing an open access to the obtained results. Of the 279 phenotypes included in GWAS, 103 displayed significant associations with 2804 SNPs (2091 unique SNPs) at Bonferroni threshold, whereas 109 of the 825 phenotypes included in EWAS analyses were associated with 4893 CpGs (2578 unique CpGs). All of the obtained GWAS and EWAS results were eventually made available using the in-house built web-based PhenoExplorer platform, with the purpose of providing an open-access to the tested associations. In conclusion, we provide a comprehensive outline of GWAS and EWAS associations performed in a Swiss population-based study. Further, we set up a web-based PhenoExplorer platform with the purpose of contributing to the overall understanding of the role of molecular variants in regulating complex phenotypes.
Collapse
Affiliation(s)
- Jean-Pierre Ghobril
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland.
| | - Dusan Petrovic
- University Center for General Medicine and Public Health (UNISANTE).
| | - Georg Ehret
- Department of Cardiology, Geneva University Hospitals (HUG), Geneva, Switzerland.
| | - Belén Ponte
- Department of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland.
| | - Menno Pruijm
- Department of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
| | - Daniel Ackermann
- University Clinical for Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern, Switzerland.
| | - Bruno Vogt
- University Clinical for Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern, Switzerland.
| | - Silvia Stringhini
- Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
| | - Aurélien Thomas
- Unit of Forensic Toxicology and Chemistry, CURML, Lausanne University Hospital-Geneva University Hospitals, Lausanne-Geneva, Switzerland.
| | - Jonviea Chamberlain
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland.
| | - Semira Gonseth-Nusslé
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland.
| | - Murielle Bochud
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland.
| |
Collapse
|
9
|
Meach S, Huber A, Jimaja W, Carrera E, Ponte B. [How to manage hypertension after an ischemic or hemorrhagic stroke?]. Rev Med Suisse 2022; 18:1702-1707. [PMID: 36103121 DOI: 10.53738/revmed.2022.18.795.1702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The sometimes-divergent results of studies on the management of blood pressure in the acute phase of stroke have not led to strong and generalizable recommendations. Indeed, an individualized approach seems to be necessary. Depending on the etiology of the stroke, the time to introduce blood pressure lowering therapy differs. In hemorrhagic stroke, it is recommended that intensive hypotensive therapy be started immediately aiming a systolic blood pressure of 130-140mmHg, whereas in the management of ischemic stroke, no hypotensive therapy should be introduced within the first 24 hours except if thrombectomy or thrombolysis are performed. No antihypertensive agent has clearly demonstrated superiority over other classes. However, abrupt changes in blood pressure should be avoided.
Collapse
Affiliation(s)
- Stefania Meach
- Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Aurélie Huber
- Faculté de médecine, Université de Genève, 1211 Genève 4
| | - Wedali Jimaja
- Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Emmanuel Carrera
- Stroke Center et Service de neurologie, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Belén Ponte
- Service de néphrologie et hypertension, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
10
|
Ponte B, Wuerzner G, Pechère-Bertschi A. [Not Available]. Rev Med Suisse 2022; 18:1687. [PMID: 36103117 DOI: 10.53738/revmed.2022.18.795.1687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Affiliation(s)
- Belén Ponte
- Service de néphrologie et hypertension, Département de médecine, Hôpitaux universitaires de Genève
| | - Grégoire Wuerzner
- Service de néphrologie et hypertension, Département de médecine, Centre hospitalier universitaire vaudois et Université de Lausanne
| | | |
Collapse
|
11
|
Da Costa C, Leszek Paccolat C, Ponte B. [Sodium, potassium and arterial hypertension: what's new?]. Rev Med Suisse 2022; 18:1694-1697. [PMID: 36103119 DOI: 10.53738/revmed.2022.18.795.1694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
High blood pressure is a public health problem, causing high morbidity and mortality. Its prevalence could exceed 1.5 billion of cases by 2025. High-salt diets have been recognized for several years as a major contributor to elevated blood pressure, with a curvilinear relationship between salt load and increased systolic and diastolic values. On the contrary, potassium is considered as protective, with lower blood pressure values in populations consuming a lot of fruits and vegetables. The World Health Organisation has established recommendations, with a target consumption of less than 218 mmol and more than 90 mmol per day, of salt and potassium, respectively. In this review article, we cover the most recent evidence allowing to sustain those recommendations.
Collapse
Affiliation(s)
- César Da Costa
- Service de médecine interne générale, Département de médecine interne, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Céline Leszek Paccolat
- Service de néphrologie, Département des spécialités de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Belén Ponte
- Service de néphrologie, Département des spécialités de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
12
|
Jaques D, Haidar F, Dufey A, Ponte B, Carballo S, de Seigneux S, Saudan P. MO886: Outcomes in Incident Patients Treated With Incremental Haemodialysis as Compared With Thrice-Weekly Haemodialysis and Peritoneal Dialysis: The Geneva Experience. Nephrol Dial Transplant 2022. [DOI: 10.1093/ndt/gfac083.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND AND AIMS
Preservation of residual kidney function (RKF) in maintenance haemodialysis (HD) patients is associated with better survival and quality of life. RKF may be better preserved with an incremental HD (frequency < 3x/week) regimen in patients starting HD. Since 2013, incremental HD is routinely used at our centre.
METHOD
Incremental HD was implemented in incident HD patients with a urine output of >600 mL/day, a urea clearance (KRU) ≥2 mL/min and an interdialytic weight gain < 2.5 kg. Patients were clinically assessed every week and a 24-h urine collection was ordered every other month in order to measure RKF.
RESULTS
From January 2013 to December 2020, 296 patients started chronic dialysis, with 162 on thrice-weekly HD, 63 on incremental HD and 71 on peritoneal dialysis (PD). Patients on incremental HD did not differ from those on thrice-weekly HD or PD in terms of age, gender and comorbidity score. Diuresis, eGFR and KRU at incremental HD initiation were 1842 ± 749 mL/day, 6.7 ± 3.1 mL/min and 4.0 ± 1.8 mL/min, respectively. Among patients on incremental HD, four could retrieve a sufficient RKF to become dialysis-independent and two were transplanted. Among the 57 remaining patients on incremental HD, median duration until transition to a thrice-weekly HD regimen or death was 10 (6–20) months. Within the first year of dialysis, median survival and hospital-free days were higher in patients starting with incremental HD as compared with thrice-weekly HD: 91% versus 77%, P = 0.02 and 348 (316–362) versus 338 (295–354) days; P = 0.03.
CONCLUSION
These preliminary results show that incremental HD can be implemented in incident HD patients as long as regular clinical and RKF assessments are found adequate. A median duration of 10 months before transition to thrice-weekly HD can be expected in this setting. Results of randomised clinical trials assessing long-term survival and quality of life in incremental HD are awaited prior to its large-scale implementation.
Collapse
Affiliation(s)
- David Jaques
- Nephrology, Geneva University Hospitals, Switzerland
| | - Fadi Haidar
- Nephrology, Geneva University Hospitals, Switzerland
| | - Anne Dufey
- Nephrology, Geneva University Hospitals, Switzerland
| | - Belén Ponte
- Nephrology, Geneva University Hospitals, Switzerland
| | | | | | | |
Collapse
|
13
|
Abstract
Kidneys undergo structural as well as functional aging. Imaging and microscopic exams show alterations that manifest as a decline in glo merular filtration rate (GFR) over time. As a GFR < 60 ml/min/1,73m2 during more than three months is sufficient to diagnose chronic kidney disease (CKD), a large proportion of elderly fall into this category. However, morphological, clinical and epidemiological data show that the decline in GFR with age is not per se associated with adverse consequences. An age-adapted definition of CKD would allow managing patients on an individual prognostic basis rather than on an arbitrary biological construct.
Collapse
Affiliation(s)
- Ephrem Clerc
- Faculté de médecine, Université de Genève, 1211 Genève
| | - Belén Ponte
- Service de néphrologie et hypertension, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - David Jaques
- Service de néphrologie et hypertension, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
14
|
Petrovic D, Pruijm M, Ponte B, Dhayat NA, Ackermann D, Ehret G, Ansermot N, Vogt B, Martin PY, Stringhini S, Estoppey-Younès S, Thijs L, Zhang Z, Melgarejo JD, Eap CB, Staessen JA, Bochud M, Guessous I. Investigating the Relations Between Caffeine-Derived Metabolites and Plasma Lipids in 2 Population-Based Studies. Mayo Clin Proc 2021; 96:3071-3085. [PMID: 34579945 DOI: 10.1016/j.mayocp.2021.05.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 04/22/2021] [Accepted: 05/27/2021] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To investigate the relations between caffeine-derived metabolites (methylxanthines) and plasma lipids by use of population-based data from 2 European countries. METHODS Families were randomly selected from the general population of northern Belgium (FLEMENGHO), from August 12, 1985, until November 22, 1990, and 3 Swiss cities (SKIPOGH), from November 25, 2009, through April 4, 2013. We measured plasma concentrations (FLEMENGHO, SKIPOGH) and 24-hour urinary excretions (SKIPOGH) of 4 methylxanthines-caffeine, paraxanthine, theobromine, and theophylline-using ultra-high-performance liquid chromatography-tandem mass spectrometry. We used enzymatic methods to estimate total cholesterol, high-density lipoprotein cholesterol, and triglyceride levels and the Friedewald equation for low-density lipoprotein cholesterol levels in plasma. We applied sex-specific mixed models to investigate associations between methylxanthines and plasma lipids, adjusting for major confounders. RESULTS In both FLEMENGHO (N=1987; 1055 [53%] female participants) and SKIPOGH (N=990; 523 [53%] female participants), total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels increased across quartiles of plasma caffeine, paraxanthine, and theophylline (total cholesterol levels by caffeine quartiles in FLEMENGHO, male participants: 5.01±0.06 mmol/L, 5.05±0.06 mmol/L, 5.27±0.06 mmol/L, 5.62±0.06 mmol/L; female participants: 5.24±0.06 mmol/L, 5.15±0.05 mmol/L, 5.25±0.05 mmol/L, 5.42±0.05 mmol/L). Similar results were observed using urinary methylxanthines in SKIPOGH (total cholesterol levels by caffeine quartiles, male participants: 4.54±0.08 mmol/L, 4.94±0.08 mmol/L, 4.87±0.08 mmol/L, 5.27±0.09 mmol/L; female participants: 5.12±0.07 mmol/L, 5.21±0.07 mmol/L, 5.28±0.05 mmol/L, 5.28±0.07 mmol/L). Furthermore, urinary caffeine and theophylline were positively associated with high-density lipoprotein cholesterol in SKIPOGH male participants. CONCLUSION Plasma and urinary caffeine, paraxanthine, and theophylline were positively associated with plasma lipids, whereas the associations involving theobromine were less clear. We postulate that the positive association between caffeine intake and plasma lipids may be related to the sympathomimetic function of methylxanthines, mitigating the overall health-beneficial effect of caffeine intake.
Collapse
Affiliation(s)
- Dusan Petrovic
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland; Department and Division of Primary Care Medicine, Geneva University Hospitals (HUG), Switzerland; Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
| | - Menno Pruijm
- Department of Nephrology and Hypertension, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland
| | - Belén Ponte
- Department of Nephrology and Hypertension, Geneva University Hospitals (HUG), Switzerland
| | - Nasser A Dhayat
- Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Daniel Ackermann
- Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Georg Ehret
- Department of Cardiology, Geneva University Hospitals (HUG), Switzerland
| | - Nicolas Ansermot
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Prilly, Switzerland
| | - Bruno Vogt
- Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Pierre-Yves Martin
- Department of Nephrology and Hypertension, Geneva University Hospitals (HUG), Switzerland
| | - Silvia Stringhini
- Department and Division of Primary Care Medicine, Geneva University Hospitals (HUG), Switzerland
| | - Sandrine Estoppey-Younès
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
| | - Lutgarde Thijs
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven, Department of Cardiovascular Sciences, University of Leuven, Belgium
| | - Zhenyu Zhang
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven, Department of Cardiovascular Sciences, University of Leuven, Belgium
| | - Jesus D Melgarejo
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven, Department of Cardiovascular Sciences, University of Leuven, Belgium
| | - Chin B Eap
- Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland; Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Prilly, Switzerland; School of Pharmaceutical Sciences, University of Geneva (UNIGE), Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva (UNIGE), Geneva, and University of Lausanne (UNIL), Lausanne, Switzerland
| | - Jan A Staessen
- Research Institute Alliance for Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium; Biomedical Sciences Group, Faculty of Medicine, University of Leuven, Leuven, Belgium
| | - Murielle Bochud
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland.
| | - Idris Guessous
- Department and Division of Primary Care Medicine, Geneva University Hospitals (HUG), Switzerland.
| |
Collapse
|
15
|
Tessitore E, Dobretz K, Dhayat NA, Estoppey S, Kern I, Ponte B, Pruijm M, Vogt B, Vuilleumier N, Bochud M, Mach F, Ehret G. Lipoprotein(a) levels are not independently associated with endogenous steroid hormone levels, in contrast to other non-genetic and genetic factors: the population-based SKIPOGH study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Lipoprotein(a) [Lp(a)] is an LDL-like molecule that is likely causally related to cardiovascular events. Lp(a) levels are highly variable, by more two orders of magnitude, and most of this variability appears to be of genetic origin. Exogenous hormones (hormone replacement therapy) seem to influence Lp(a) levels, but the impact of the variation of endogenous hormone levels on Lp(a) is unknown.
Purpose
To investigate the association between Lp(a) levels and non-genetic factors, as endogenous steroid hormone levels, in contrast to genetic factors.
Methods
We investigated the association of 28 endogenous steroids with Lp(a) levels and compared the association to other non-genetic and genetic variables in a prospective, population-based sample (N=1,021).
Results
The average age of the participants was 51 years and 53% were female. Median Lp(a) levels were 62 (±204) mg/l and the 90th and 99th percentile of Lp(a) was 616mg/l and 1035 mg/l respectively. The prevalence of a Lp(a) elevation ≥700mg/l was 3.2% and Lp(a) varied greatly from undetectable to 1,690mg/l. Age explained 2.0% of Lp(a) variability (p<0.001), 1% was explained by LDL levels (p=0.001), and 40% by two single nucleotide polymorphisms near the Lp(a) gene that have been previously described. Lp(a) levels were on average almost two times more elevated in secondary prevention and in individuals with very elevated LDL levels (≥4.9 mmol/l). Of the 28 endogenous steroid hormones assessed, 5-androstene-3b,16α,17β-triol, androsterone, 16α-hydroxy DHEA, and estriol were nominatively associated with serum Lp(a) levels and explained 0.4–1% of Lp(a) variability in univariate analyses, but they did not reach significance in multi-variate models.
Conclusion
Our results confirm previous findings demonstrating that the majority of the Lp(a) variation in the general population is of genetic origin. Age and LDL-levels explain a further small part of Lp(a) variability. Endogenous hormone levels do not contribute significantly to the wide range of variability.
Funding Acknowledgement
Type of funding sources: None. Coefficient plot Lp(a) and variables
Collapse
Affiliation(s)
- E Tessitore
- University Hospital of Geneva, Department of Cardiology, Geneva, Switzerland
| | - K Dobretz
- University Hospital of Geneva, Department of Cardiology, Geneva, Switzerland
| | - N A Dhayat
- Inselspital - University of Bern, Department of Nephrology and Hypertension, Bern, Switzerland
| | - S Estoppey
- Centre for Primary Care and Public Health (Unisante), Lausanne, Switzerland
| | - I Kern
- Geneva University Hospitals, Geneva, Switzerland
| | - B Ponte
- Geneva University Hospitals, Department of Nephrology and Hypertension, Geneva, Switzerland
| | - M Pruijm
- University Hospital Centre Vaudois (CHUV), Department of Nephrology, Lausanne, Switzerland
| | - B Vogt
- Inselspital - University of Bern, Department of Nephrology and Hypertension, Bern, Switzerland
| | | | - M Bochud
- Centre for Primary Care and Public Health (Unisante), Lausanne, Switzerland
| | - F Mach
- University Hospital of Geneva, Department of Cardiology, Geneva, Switzerland
| | - G Ehret
- University Hospital of Geneva, Department of Cardiology, Geneva, Switzerland
| |
Collapse
|
16
|
Wuerzner G, Ponte B, Meylan S, Pechère-Bertschi A. [Not Available]. Rev Med Suisse 2021; 17:1547. [PMID: 34528416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- Grégoire Wuerzner
- Service de néphrologie et hypertension, Département de médecine, CHUV et Université de Lausanne, Lausanne
| | - Belén Ponte
- Service de néphrologie et hypertension, Département de médecine, HUG, Genève
| | | | | |
Collapse
|
17
|
Alves C, Zekry D, Ponte B. [Hypertension and dementia : A complex link]. Rev Med Suisse 2021; 17:1567-1570. [PMID: 34528420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
High blood pressure and dementia are both frequent age-related diseases. The purpose of this article is to review the treatment of hypertension and his effects on cognition, and to propose key points to improve hypertension's treatment in dementia suffering patients. The management of hypertension in middle-life patients seems to be very important to avoid or decrease the progression of cognitive impairment or dementia. Nevertheless, there is no guidelines regarding blood pressure in patients concerned by dementia. To personalize the treatment, to take other comorbidities into account, and the frequent reevaluation of the medication are keys of an optimal management of hypertension in general and becomes crucial more specific in this population.
Collapse
Affiliation(s)
- Cyrielle Alves
- Service de néphrologie et hypertension, Département des spécialités de médecine, HUG, 1211 Genève 14
| | - Dina Zekry
- Service de médecine interne de l'âgé, Département de réadaptation et gériatrie, HUG, 1211 Genève 14
| | - Belén Ponte
- Service de néphrologie et hypertension, Département des spécialités de médecine, HUG, 1211 Genève 14
| |
Collapse
|
18
|
Boccard J, Schvartz D, Codesido S, Hanafi M, Gagnebin Y, Ponte B, Jourdan F, Rudaz S. Gaining Insights Into Metabolic Networks Using Chemometrics and Bioinformatics: Chronic Kidney Disease as a Clinical Model. Front Mol Biosci 2021; 8:682559. [PMID: 34055893 PMCID: PMC8163225 DOI: 10.3389/fmolb.2021.682559] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 04/19/2021] [Indexed: 01/21/2023] Open
Abstract
Because of its ability to generate biological hypotheses, metabolomics offers an innovative and promising approach in many fields, including clinical research. However, collecting specimens in this setting can be difficult to standardize, especially when groups of patients with different degrees of disease severity are considered. In addition, despite major technological advances, it remains challenging to measure all the compounds defining the metabolic network of a biological system. In this context, the characterization of samples based on several analytical setups is now recognized as an efficient strategy to improve the coverage of metabolic complexity. For this purpose, chemometrics proposes efficient methods to reduce the dimensionality of these complex datasets spread over several matrices, allowing the integration of different sources or structures of metabolic information. Bioinformatics databases and query tools designed to describe and explore metabolic network models offer extremely useful solutions for the contextualization of potential biomarker subsets, enabling mechanistic hypotheses to be considered rather than simple associations. In this study, network principal component analysis was used to investigate samples collected from three cohorts of patients including multiple stages of chronic kidney disease. Metabolic profiles were measured using a combination of four analytical setups involving different separation modes in liquid chromatography coupled to high resolution mass spectrometry. Based on the chemometric model, specific patterns of metabolites, such as N-acetyl amino acids, could be associated with the different subgroups of patients. Further investigation of the metabolic signatures carried out using genome-scale network modeling confirmed both tryptophan metabolism and nucleotide interconversion as relevant pathways potentially associated with disease severity. Metabolic modules composed of chemically adjacent or close compounds of biological relevance were further investigated using carbon transfer reaction paths. Overall, the proposed integrative data analysis strategy allowed deeper insights into the metabolic routes associated with different groups of patients to be gained. Because of their complementary role in the knowledge discovery process, the association of chemometrics and bioinformatics in a common workflow is therefore shown as an efficient methodology to gain meaningful insights in a clinical context.
Collapse
Affiliation(s)
- Julien Boccard
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Domitille Schvartz
- Translational Biomarker Group, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Santiago Codesido
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Mohamed Hanafi
- Unité Statistique, Sensométrie et Chimiométrie, Nantes, France
| | - Yoric Gagnebin
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Belén Ponte
- Service of Nephrology and Hypertension, Department of Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Fabien Jourdan
- Toxalim, Research Centre in Food Toxicology, Université de Toulouse, INRAE, ENVT, INP-Purpan, UPS, Toulouse, France
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| |
Collapse
|
19
|
Pechère-Bertschi A, Olivier V, Burnier M, Udwan K, de Seigneux S, Ponte B, Maillard M, Martin PY, Feraille E. Dietary sodium intake does not alter renal potassium handling and blood pressure in healthy young males. Nephrol Dial Transplant 2021; 37:548-557. [PMID: 33492394 PMCID: PMC8875469 DOI: 10.1093/ndt/gfaa381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Indexed: 12/03/2022] Open
Abstract
Background The effects of sodium (Na+) intakes on renal handling of potassium (K+) are insufficiently studied. Methods We assessed the effect of Na+ on renal K+ handling in 16 healthy males assigned to three 7-day periods on low salt diet [LSD, 3 g sodium chloride (NaCl)/day], normal salt diet (NSD, 6 g NaCl/day) and high salt diet (HSD, 15 g NaCl/day), with constant K+ intake. Contributions of distal NaCl co-transporter and epithelial Na+ channel in the collecting system on K+ and Na+ handling were assessed at steady state by acute response to 100 mg oral hydrochlorothiazide and with addition of 10 mg of amiloride to hydrochlorothiazide, respectively. Results Diurnal blood pressure slightly increased from 119.30 ± 7.95 mmHg under LSD to 123.00 ± 7.50 mmHg (P = 0.02) under HSD, while estimated glomerular filtration rate increased from 133.20 ± 34.68 mL/min under LSD to 187.00 ± 49.10 under HSD (P = 0.005). The 24-h K+ excretion remained stable on all Na+ intakes (66.28 ± 19.12 mmol/24 h under LSD; 55.91 ± 21.17 mmol/24 h under NSD; and 66.81 ± 20.72 under HSD, P = 0.9). The hydrochlorothiazide-induced natriuresis was the highest under HSD (30.22 ± 12.53 mmol/h) and the lowest under LSD (15.38 ± 8.94 mmol/h, P = 0.02). Hydrochlorothiazide increased kaliuresis and amiloride decreased kaliuresis similarly on all three diets. Conclusions Neither spontaneous nor diuretic-induced K+ excretion was influenced by Na+ intake in healthy male subjects. However, the respective contribution of the distal convoluted tubule and the collecting duct to renal Na+ handling was dependent on dietary Na+ intake.
Collapse
Affiliation(s)
| | - Valérie Olivier
- Service of Nephrology and Hypertension, University Hospital Geneva, Switzerland.,Department of Cell Physiology and Metabolism, University of Geneva, Switzerland
| | - Michel Burnier
- Service of Nephrology and Hypertension, CHUV, Lausanne, Switzerland
| | - Khalil Udwan
- Department of Cell Physiology and Metabolism, University of Geneva, Switzerland
| | - Sophie de Seigneux
- Service of Nephrology and Hypertension, University Hospital Geneva, Switzerland.,Department of Cell Physiology and Metabolism, University of Geneva, Switzerland
| | - Belén Ponte
- Service of Nephrology and Hypertension, University Hospital Geneva, Switzerland
| | - Marc Maillard
- Service of Nephrology and Hypertension, CHUV, Lausanne, Switzerland
| | - Pierre-Yves Martin
- Service of Nephrology and Hypertension, University Hospital Geneva, Switzerland.,Department of Cell Physiology and Metabolism, University of Geneva, Switzerland
| | - Eric Feraille
- Service of Nephrology and Hypertension, University Hospital Geneva, Switzerland.,Department of Cell Physiology and Metabolism, University of Geneva, Switzerland
| |
Collapse
|
20
|
Gagnebin Y, Jaques DA, Rudaz S, de Seigneux S, Boccard J, Ponte B. Exploring blood alterations in chronic kidney disease and haemodialysis using metabolomics. Sci Rep 2020; 10:19502. [PMID: 33177589 PMCID: PMC7658362 DOI: 10.1038/s41598-020-76524-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 10/29/2020] [Indexed: 02/06/2023] Open
Abstract
Chronic kidney disease (CKD) is characterized by retention of uremic solutes. Compared to patients with non-dialysis dependent CKD, those requiring haemodialysis (HD) have increased morbidity and mortality. We wished to characterise metabolic patterns in CKD compared to HD patients using metabolomics. Prevalent non-HD CKD KDIGO stage 3b-4 and stage 5 HD outpatients were screened at a single tertiary hospital. Various liquid chromatography approaches hyphenated with mass spectrometry were used to identify 278 metabolites. Unsupervised and supervised data analyses were conducted to characterize metabolic patterns. 69 patients were included in the CKD group and 35 in the HD group. Unsupervised data analysis showed clear clustering of CKD, pre-dialysis (preHD) and post-dialysis (postHD) patients. Supervised data analysis revealed qualitative as well as quantitative differences in individual metabolites profiles between CKD, preHD and postHD states. An original metabolomics framework could discriminate between CKD stages and highlight HD effect based on 278 identified metabolites. Significant differences in metabolic patterns between CKD and HD patients were found overall as well as for specific metabolites. Those findings could explain clinical discrepancies between patients requiring HD and those with earlier stage of CKD.
Collapse
Affiliation(s)
- Yoric Gagnebin
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - David A Jaques
- Service of Nephrology and Hypertension, Department of Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
- Swiss Centre for Applied Human Toxicology, University of Basel, Basel, Switzerland
| | - Sophie de Seigneux
- Service of Nephrology and Hypertension, Department of Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland
| | - Julien Boccard
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
- Swiss Centre for Applied Human Toxicology, University of Basel, Basel, Switzerland
| | - Belén Ponte
- Service of Nephrology and Hypertension, Department of Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland
| |
Collapse
|
21
|
Dash J, Pruijm M, Ponte B. [The role of kidney ultrasound in patients with arterial hypertension]. Rev Med Suisse 2020; 16:1676-1679. [PMID: 32936547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The kidneys play a central role in the regulation of blood pressure and are also one of the main culprits of arterial hypertension (HT). Renal ultrasound is a valuable diagnostic tool that can provide instant information at the bedside on possible underlying causes and consequences of HT. Its role in the screening for renal artery stenosis is well-known. However, renal ultrasound can also detect abnormalities in renal parenchyma, morphology, or the vascularization of the kidneys, and as such directly influence further diagnostic work-up and treatment. The significance of the renal resistive index and the place of renal ultrasound in the latest international guidelines on HT are reviewed in this article.
Collapse
Affiliation(s)
- Jonathan Dash
- Service de médecine interne, Département de médecine interne, HUG, 1211 Genève 14
| | - Menno Pruijm
- Service de néphrologie et hypertension, CHUV, 1011 Lausanne
| | - Belén Ponte
- Service de néphrologie et hypertension, Département de médecine interne, HUG, 1211 Genève 14
| |
Collapse
|
22
|
Petrovic D, Pruijm M, Ponte B, Ackermann D, Ehret G, Zhang Z, Thijs L, Staessen J, Bochud M, Guessous I. Exploring the relation between methylxanthines and plasma lipids in two population-based studies. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Chronic intake of caffeinated beverages might be associated with plasma lipids via disturbed lipid metabolism. Previous investigations have been limited by the use of self-reported caffeine intake instead of measured caffeine, whereas the associations between plasma lipids and other methylxanthines (paraxanthine, theobromine, theophylline) are unknown. Here, we investigated the associations of plasma lipids with caffeine and its metabolites in plasma and urine in two European populations.
Methods
Individuals were selected from the general population of North Belgium (FLEMENGHO) and Switzerland (SKIPOGH). Total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were measured in plasma using standard enzymatic methods. Plasma and 24h urinary caffeine, paraxanthine, theophylline, and theobromine excretions were measured using ultra-high performance liquid chromatography tandem mass spectrometry. We used mixed models to explore the associations of methylxanthines with plasma lipids while adjusting for major confounders.
Results
Overall, 1946 FLEMENGHO participants (911 men, age 45.9±15.2 years) and 990 SKIPOGH participants (467 men, age 47.1±17.3 years) were included. Mean plasma total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides in FLEMENGHO/SKIPOGH were 5.37/5.06, 3.12/3.12, 1.43/1.50, and 2.4/1.02 mmol/L. In both cohorts, adjusted mean total cholesterol, LDL cholesterol, and HDL cholesterol, increased with quartile of plasma caffeine, with stronger associations in men. Similar positive associations were observed for paraxanthine and theophylline. Similar associations were observed using 24h urine excretions in SKIPOGH.
Conclusions
Plasma and urinary caffeine, paraxanthine, and theophylline were positively associated with plasma lipids in men, whereas there were fewer meaningful associations in women. The increase in plasma lipids might mitigate the overall beneficial impact of caffeinated beverages on health.
Key messages
Caffeine constitutes one of the most widely consumed biological active substances. Plasma concentration and urinary excretion of caffeine and its derived metabolites is positively associated with plasma lipids.
Collapse
Affiliation(s)
- D Petrovic
- DESS, Unisanté-Centre universitaire de médecine générale et santé publique, Lausanne, Switzerland
| | - M Pruijm
- Department of Nephrology and Hypertension, Lausanne University Hospital, Lausanne, Switzerland
| | - B Ponte
- Department of Nephrology and Hypertension, University Hospital of Geneva, Geneva, Switzerland
| | - D Ackermann
- University Clinic for Nephrology, Hypertension and Clinic, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
| | - G Ehret
- Department of Cardiology, University Hospital of Geneva, Geneva, Switzerland
| | - Z Zhang
- Studies Coordinating Centre, Research Unit Hypertension a, University Leuven, Leuven, Belgium
| | - L Thijs
- Studies Coordinating Centre, Research Unit Hypertension a, University Leuven, Leuven, Belgium
| | - J Staessen
- Studies Coordinating Centre, Research Unit Hypertension a, University Leuven, Leuven, Belgium
| | - M Bochud
- DESS, Unisanté-Centre universitaire de médecine générale et santé publique, Lausanne, Switzerland
| | - I Guessous
- Department of Community Medicine and Primary Care and Eme, University Hospital of Geneva, Geneva, Switzerland
| |
Collapse
|
23
|
Petrovic D, Carmeli C, Bodinier B, Chadeau-Hyam M, Ehret G, Dhayat N, Ponte B, Pruijm M, Bochud M, Stringhini S. Exploring the relation between socioeconomic position and DNA methylation in a European population. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa165.1045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Previous investigations have reported that adverse socioeconomic circumstances across the life-course lead to the alteration of major biological processes, eventually resulting in a higher disease risk and premature death. In particular, a low life-course socioeconomic position (SEP) has been associated with a modified epigenetic signature of loci involved in inflammation, the physiological response to stress, and other regulatory processes.
Methods
In this study, we investigated the association between nine indicators of SEP across the life-course and the differential methylation of 451'000 genome-wide CpG markers, using data from 690 adults included in a Swiss population-based study. We further examined the interrelations between the SEP-related CpGs, and the biological pathways in which the identified markers are involved.
Results
Three SEP indicators in adulthood were associated the differential methylation of 161 genome-wide CpG markers, whereby 156 CpGs were less methylated in people with low versus high SEP. Among the identified CpGs, a substantial proportion of markers were no longer associated with SEP upon accounting for health behaviors and cardiometabolic disorders. In addition, the identified CpGs were found to be involved in immune, inflammatory, and cancer-related processes.
Conclusions
Our results support the hypothesis that adverse socioeconomic circumstances may lead to the dysregulation of inflammatory processes, eventually resulting in the occurrence of serious chronic conditions such as atherosclerosis, diabetes, or cancer.
Key messages
Socioeconomic position is a major determinant of health-related outcomes. Epigenetic modifications may constitute a biological mechanism through which socioeconomic circumstances affect health.
Collapse
Affiliation(s)
- D Petrovic
- Department of Epidemiology and Health Systems, Unisanté-Centre universitaire de médecine générale et santé publique, Lausanne, Switzerland
| | - C Carmeli
- Department of Epidemiology and Health Systems, Unisanté-Centre universitaire de médecine générale et santé publique, Lausanne, Switzerland
| | - B Bodinier
- Centre for Environment and Health, School of Public Health, Imperial College London, London, UK
| | - M Chadeau-Hyam
- Centre for Environment and Health, School of Public Health, Imperial College London, London, UK
| | - G Ehret
- Department of Cardiology, University Hospital of Geneva, Geneva, Switzerland
| | - N Dhayat
- University Clinic for Nephrology and Hypertension, Bern University Hospital, Bern, Switzerland
| | - B Ponte
- Department of Nephrology and Hypertension, University Hospital of Geneva, Geneva, Switzerland
| | - M Pruijm
- Department of Nephrology and Hypertension, Lausanne University Hospital, Lausanne, Switzerland
| | - M Bochud
- Department of Epidemiology and Health Systems, Unisanté-Centre universitaire de médecine générale et santé publique, Lausanne, Switzerland
| | - S Stringhini
- Department of Epidemiology and Health Systems, Unisanté-Centre universitaire de médecine générale et santé publique, Lausanne, Switzerland
- Unit of Population Epidemiology, Primary Care Division, University Hospital of Geneva, Geneva, Switzerland
| |
Collapse
|
24
|
Pechère-Bertschi A, Ponte B, Wuerzner G. [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?]. Rev Med Suisse 2020; 16:1003-1007. [PMID: 32401442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
ACE2 is not only an enzyme that counters the effects of the renin-angiotensin-aldosterone system (RAAS) but is also the entry receptor for SARS-CoV-2, the virus of the Covid-19 pandemic. Some experimental data suggest that ACE inhibitors and ARBs increase ACE2 levels, thus raising concerns on their security in Covid-19 positive patients. However, some studies have shown protection by these drugs in lower tract respiratory infections and ARDS. The actual consensus is to continue the treatment with RAAS inhibitors, abrupt withdrawal, especially in patients with cardiac or renal conditions, being hazardous in terms of cardiovascular outcomes, except in patients hospitalized in intensive care with hemodynamic instability. This position statement is actually unanimous among all international learned societies.
Collapse
Affiliation(s)
| | - Belén Ponte
- Service de néphrologie et hypertension, HUG, 1205 Genève
| | | |
Collapse
|
25
|
Gagnebin Y, Pezzatti J, Lescuyer P, Boccard J, Ponte B, Rudaz S. Toward a better understanding of chronic kidney disease with complementary chromatographic methods hyphenated with mass spectrometry for improved polar metabolome coverage. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1116:9-18. [PMID: 30951967 DOI: 10.1016/j.jchromb.2019.03.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 03/19/2019] [Accepted: 03/25/2019] [Indexed: 12/25/2022]
Abstract
The prevalence of chronic kidney disease (CKD) is increasing worldwide. New technical approaches are needed to improve early diagnosis, disease understanding and patient monitoring, and to evaluate new therapies. Metabolomics, as a prime candidate in the field of CKD research, aims to comprehensively analyze the metabolic complexity of biological systems. An extensive analysis of the metabolites contained in biofluids is therefore needed, and the combination of data obtained from multiple analytical platforms constitutes a promising methodological approach. This study presents an original workflow based on complementary chromatographic conditions, reversed-phase and hydrophilic interaction chromatography hyphenated to mass spectrometry to improve the polar metabolome coverage coupled with a univocal metabolite annotation strategy enabling a rapid access to the biological interpretation. This multiplatform workflow was applied in a CKD cohort study to assess plasma metabolic profile modifications related to renal disease. Multivariate analysis of 278 endogenous annotated metabolites enabled patient stratification with respect to CKD stages and helped to generate new biological insights, while also confirming the relevance of tryptophan metabolism pathway in this condition.
Collapse
Affiliation(s)
- Yoric Gagnebin
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Julian Pezzatti
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Julien Boccard
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland; Swiss Center of Human Applied Toxicology, University of Basel, Switzerland
| | - Belén Ponte
- Service of Nephrology, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland; Swiss Center of Human Applied Toxicology, University of Basel, Switzerland.
| |
Collapse
|
26
|
Canivell S, Mohaupt M, Ackermann D, Pruijm M, Guessous I, Ehret G, Escher G, Pechère-Bertschi A, Vogt B, Devuyst O, Burnier M, Martin PY, Ponte B, Bochud M. Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study. J Endocrinol Invest 2018; 41:799-808. [PMID: 29235050 DOI: 10.1007/s40618-017-0807-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Accepted: 12/05/2017] [Indexed: 12/26/2022]
Abstract
PURPOSE Arginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population. METHODS This was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18-90 years, 47% men, 13.4% MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate. RESULTS Plasma copeptin was higher in men [median 5.2, IQR (3.7-7.8) pmol/L] than in women [median 3.0, IQR (2.2-4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95% CI) = 0.32 (0.17-0.46), P < 0.001] or if age was high [β (95% CI) = 0.34 (0.20-0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95% CI) = 2.07 (1.10-3.89), P = 0.024), but not for MetS (OR (95% CI) = 1.12 (0.74-1.69), P = 0.605), after full adjustment. CONCLUSIONS Our data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.
Collapse
Affiliation(s)
- S Canivell
- Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland.
| | - M Mohaupt
- University Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - D Ackermann
- University Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - M Pruijm
- Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - I Guessous
- Department of Community Medicine, Primary Care and Emergency Medicine, University Hospital of Geneva, Geneva, Switzerland
- Institute of Social and Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland
| | - G Ehret
- Cardiology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - G Escher
- University Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - A Pechère-Bertschi
- Unit of Hypertension, Departments of Specialties of Medicine and Community Medicine and Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - B Vogt
- University Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - O Devuyst
- Institute of Physiology, University of Zurich, Zurich, Switzerland
| | - M Burnier
- Nephrology Service, University Hospital of Lausanne, Lausanne, Switzerland
- Department of Clinical Research, University of Bern, Bern, Switzerland
| | - P-Y Martin
- Nephrology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - B Ponte
- Nephrology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - M Bochud
- Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland
| |
Collapse
|
27
|
Pivin E, Ponte B, de Seigneux S, Ackermann D, Burnier M, Bochud M, Devuyst O, Pruijm M. FO044UROMODULIN REFLECTS NEPHRON MASS IN THE GENERAL POPULATION AND KIDNEY DONORS. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.fo044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Edward Pivin
- Nephrology and Hypertension, University Hospital Lausanne (CHUV), Lausanne, Switzerland
| | - Belén Ponte
- Nephrology and Hypertension, University Hospital Geneva (HUG), Geneva, Switzerland
| | - Sophie de Seigneux
- Nephrology and Hypertension, University Hospital Geneva (HUG), Geneva, Switzerland
| | - Daniel Ackermann
- University Clinic for Nephrology and Hypertension, Bern University Hospital, Inselspital, Bern, Switzerland
| | - Michel Burnier
- Nephrology and Hypertension, University Hospital Lausanne (CHUV), Lausanne, Switzerland
| | - Murielle Bochud
- Division of chronic disease, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Olivier Devuyst
- Institute of Physiology, University of Zürich, Zürich, Switzerland
| | - Menno Pruijm
- Nephrology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| |
Collapse
|
28
|
Marti-Soler H, Pommier C, Bochud M, Guessous I, Ponte B, Pruijm M, Ackermann D, Forni Ogna V, Paccaud F, Burnier M, Pechère-Bertschi A, Devuyst O, Marques-Vidal P. Seasonality of sodium and potassium consumption in Switzerland. Data from three cross-sectional, population-based studies. Nutr Metab Cardiovasc Dis 2017; 27:792-798. [PMID: 28756972 DOI: 10.1016/j.numecd.2017.06.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Revised: 06/09/2017] [Accepted: 06/21/2017] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND AIM Blood pressure displays a seasonal pattern. Whether this pattern is related to high sodium and/or low potassium intakes has not been investigated. We assessed if sodium and potassium consumption present a seasonal pattern. We also simulated the impact of seasonality of sodium consumption on systolic blood pressure levels. METHODS AND RESULTS Data from three Swiss population-based studies (n = 2845). Sodium and potassium consumption were assessed by urinary excretion using 24 h urine collection. Seasonality was assessed using the cosinor model and was adjusted for study, gender, age, body mass index, antihypertensive drug treatment, urinary creatinine and atmospheric relative humidity. The effect of sodium variation on blood pressure levels was estimated using data from a recent meta-analysis. Both sodium and potassium excretions showed a seasonal pattern. For sodium, the nadir occurred between August and October, and the peak between February and April, with a multivariate-adjusted seasonal variation (difference between peak and nadir) of 9.2 mmol. For potassium, the nadir occurred in October and the peak in April, with a multivariate-adjusted seasonal variation of 4.0 mmol. Excluding participants on antihypertensive drug treatment or stratifying the analysis by gender cancelled the seasonality of sodium consumption. The maximum impact of the seasonal variation in sodium consumption on systolic blood pressure ranged from 0.4 to 1.1 mm Hg, depending on the model considered. CONCLUSION Sodium and potassium consumptions present specific seasonal variations. These variations do not explain the seasonal variations in blood pressure levels.
Collapse
Affiliation(s)
- H Marti-Soler
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland.
| | - C Pommier
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland.
| | - M Bochud
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland.
| | - I Guessous
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland; Department of Community Medicine, Preventive care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
| | - B Ponte
- Service of Nephrology, Geneva University Hospitals, Geneva, Switzerland.
| | - M Pruijm
- Service of Nephrology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
| | - D Ackermann
- Department of Nephrology and Hypertension, Bern University Hospital, University of Bern, Bern, Switzerland.
| | - V Forni Ogna
- Service of Nephrology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
| | - F Paccaud
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland.
| | - M Burnier
- Service of Nephrology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
| | - A Pechère-Bertschi
- Department of Community Medicine, Preventive care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.
| | - O Devuyst
- Institute of Physiology, University of Zurich, Zurich, Switzerland.
| | - P Marques-Vidal
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland; Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, Lausanne, Switzerland.
| |
Collapse
|
29
|
Petrovic D, Estoppey Younes S, Pruijm M, Ponte B, Ackermann D, Ehret G, Ansermot N, Mohaupt M, Paccaud F, Vogt B, Pechère-Bertschi A, Martin PY, Burnier M, Eap CB, Bochud M, Guessous I. Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population. Nutr Metab (Lond) 2016; 13:81. [PMID: 27891166 PMCID: PMC5112879 DOI: 10.1186/s12986-016-0144-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Accepted: 11/10/2016] [Indexed: 02/07/2023] Open
Abstract
Background Caffeine intake is generally estimated by self-reported consumption, but it remains unclear how well self-report associates with metabolite urinary excretion. We investigated the associations of self-reported consumption of caffeinated drinks with urinary excretion of caffeine and its major metabolites in an adult population. Methods We used data from the population-based Swiss Kidney Project on Genes in Hypertension (SKIPOGH) study. Consumption of caffeinated coffee, decaffeinated coffee and other caffeinated beverages was assessed by self-administered questionnaire. Quantification of caffeine, paraxanthine, theobromine and theophylline was performed by ultra-high performance liquid chromatography tandem mass spectrometry in 24-h urine. Association of reported consumption of caffeinated drinks with urinary caffeine derived metabolites was determined by quantile regression. We then explored the association between urinary metabolite excretion and dichotomized weekly consumption frequency of caffeinated coffee, with Receiver Operator Characteristic (ROC) analysis. Results In the present analysis, we included 598 individuals (52% women, mean age =46 ± 17 years). Self-reported caffeinated coffee intake was positively associated with 24-h urinary excretions of paraxanthine, theophylline and caffeine (p < 0.001), whereas reported intakes of decaffeinated coffee and other caffeinated beverages showed no association. In ROC analysis, optimal discrimination between individuals consuming less than one caffeinated coffee/week, vs. at least one coffee, was obtained for 24-h urinary paraxanthine (Area Under Curve (AUC) = 0.868, 95% Confidence Interval (CI) [0.830;0.906]), with slightly lower performance for theophylline and caffeine, whereas theobromine did not allow any discrimination. Conclusion Our results suggest that reported consumption of caffeinated coffee is positively associated with 24-h urinary excretion of caffeine, paraxanthine, and theophylline, and may be used as a marker of caffeine intake for epidemiological studies. Electronic supplementary material The online version of this article (doi:10.1186/s12986-016-0144-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Dusan Petrovic
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Route de la corniche 10, Lausanne, 1010 Switzerland
| | - Sandrine Estoppey Younes
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Route de la corniche 10, Lausanne, 1010 Switzerland
| | - Menno Pruijm
- Department of Nephrology and Hypertension, Lausanne University Hospital, Rue du Bugnon 17, Lausanne, 1011 Switzerland
| | - Belén Ponte
- Department of Nephrology and Hypertension, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, Geneva, 1205 Switzerland
| | - Daniel Ackermann
- University Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, 3010 Switzerland
| | - Georg Ehret
- Department of Cardiology, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, Geneva, 1205 Switzerland
| | - Nicolas Ansermot
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly, 1008 Switzerland
| | - Markus Mohaupt
- Department of Nephrology and Hypertension, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, Geneva, 1205 Switzerland
| | - Fred Paccaud
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Route de la corniche 10, Lausanne, 1010 Switzerland
| | - Bruno Vogt
- University Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, 3010 Switzerland
| | - Antoinette Pechère-Bertschi
- Department of Nephrology and Hypertension, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, Geneva, 1205 Switzerland
| | - Pierre-Yves Martin
- Department of Nephrology and Hypertension, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, Geneva, 1205 Switzerland
| | - Michel Burnier
- Department of Nephrology and Hypertension, Lausanne University Hospital, Rue du Bugnon 17, Lausanne, 1011 Switzerland
| | - Chin B Eap
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly, 1008 Switzerland ; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Murielle Bochud
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Route de la corniche 10, Lausanne, 1010 Switzerland
| | - Idris Guessous
- Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Route de la corniche 10, Lausanne, 1010 Switzerland ; Unit of Population Epidemiology, Division of Primary Care Medicine, Department of Community Medicine and Primary Care and Emergency Medicine, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, Geneva, 1205 Switzerland ; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, USA ; Lausanne University Outpatient Clinic, Rue du Bugnon 44, Lausanne, 1011 Switzerland ; Unit of Population Epidemiology, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, Geneva, 1205 Switzerland
| |
Collapse
|
30
|
Mataix B, Alcántara A, Caro M, Montero J, Ponte B, Rodríguez de la Rúa E. Variations in the technique for autologous limbal transplantation. ACTA ACUST UNITED AC 2016; 91:501-4. [PMID: 27156033 DOI: 10.1016/j.oftal.2016.03.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 03/18/2016] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To present the results on the use of a single block limbal autograft, combined with amniotic membrane transplantation and sectoral sequential postoperative epitheliectomy of the conjunctiva in 2 patients with unilateral total limbal stem cell deficiency. CONCLUSIONS A single block limbal autograft combined with amniotic membrane transplantation may be sufficient to restore a stable corneal surface, but sometimes sequential sectoral conjunctival epitheliectomy may be required to treat anomalous epithelial remnants.
Collapse
Affiliation(s)
- B Mataix
- Sección de Superficie Ocular y Córnea, Servicio de Oftalmología, Hospital Universitario Virgen Macarena, Sevilla, España.
| | - A Alcántara
- Sección de Superficie Ocular y Córnea, Servicio de Oftalmología, Hospital Universitario Virgen Macarena, Sevilla, España
| | - M Caro
- Sección de Superficie Ocular y Córnea, Servicio de Oftalmología, Hospital Universitario Virgen Macarena, Sevilla, España
| | - J Montero
- Sección de Superficie Ocular y Córnea, Servicio de Oftalmología, Hospital Universitario Virgen Macarena, Sevilla, España
| | - B Ponte
- Sección de Superficie Ocular y Córnea, Servicio de Oftalmología, Hospital Universitario Virgen Macarena, Sevilla, España
| | - E Rodríguez de la Rúa
- Sección de Superficie Ocular y Córnea, Servicio de Oftalmología, Hospital Universitario Virgen Macarena, Sevilla, España
| |
Collapse
|
31
|
Guessous I, Pruijm M, Ponte B, Ackermann D, Ehret G, Ansermot N, Vuistiner P, Staessen J, Gu Y, Paccaud F, Mohaupt M, Vogt B, Pechère-Bertschi A, Martin PY, Burnier M, Eap CB, Bochud M. Associations of Ambulatory Blood Pressure With Urinary Caffeine and Caffeine Metabolite Excretions. Hypertension 2015; 65:691-6. [DOI: 10.1161/hypertensionaha.114.04512] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Intake of caffeinated beverages might be associated with reduced cardiovascular mortality possibly via the lowering of blood pressure. We estimated the association of ambulatory blood pressure with urinary caffeine and caffeine metabolites in a population-based sample. Families were randomly selected from the general population of Swiss cities. Ambulatory blood pressure monitoring was conducted using validated devices. Urinary caffeine, paraxanthine, theophylline, and theobromine excretions were measured in 24 hours urine using ultrahigh performance liquid chromatography tandem mass spectrometry. We used mixed models to explore the associations of urinary excretions with blood pressure although adjusting for major confounders. The 836 participants (48.9% men) included in this analysis had mean age of 47.8 and mean 24-hour systolic and diastolic blood pressure of 120.1 and 78.0 mm Hg. For each doubling of caffeine excretion, 24-hour and night-time systolic blood pressure decreased by 0.642 and 1.107 mm Hg (both
P
values <0.040). Similar inverse associations were observed for paraxanthine and theophylline. Adjusted night-time systolic blood pressure in the first (lowest), second, third, and fourth (highest) quartile of paraxanthine urinary excretions were 110.3, 107.3, 107.3, and 105.1 mm Hg, respectively (
P
trend <0.05). No associations of urinary excretions with diastolic blood pressure were generally found, and theobromine excretion was not associated with blood pressure. Anti-hypertensive therapy, diabetes mellitus, and alcohol consumption modify the association of caffeine urinary excretion with systolic blood pressure. Ambulatory systolic blood pressure was inversely associated with urinary excretions of caffeine and other caffeine metabolites. Our results are compatible with a potential protective effect of caffeine on blood pressure.
Collapse
Affiliation(s)
- Idris Guessous
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Menno Pruijm
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Belén Ponte
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Daniel Ackermann
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Georg Ehret
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Nicolas Ansermot
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Philippe Vuistiner
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Jan Staessen
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Yumei Gu
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Fred Paccaud
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Markus Mohaupt
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Bruno Vogt
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Antoinette Pechère-Bertschi
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Pierre-Yves Martin
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Michel Burnier
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Chin B. Eap
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| | - Murielle Bochud
- From the Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine (I.G.), Service of Nephrology, Department of Specialties (B.P., P.-Y.M.), Department of Cardiology (G.E.), and Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine (I.G., A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (IUMSP) (I.G., B.P., G.E., P.V., F.P., M.B.), and Department of Medicine,
| |
Collapse
|
32
|
de la Fuente V, Stucker F, Alves C, Ponte B, Rutschmann O, Vuilleumier N, Martin P, Carballo S, Saudan P. IRA acquise en communauté : une étude prospective observationnelle. Nephrol Ther 2014. [DOI: 10.1016/j.nephro.2014.07.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Ponte B, Alves C, Stucker F, de la Fuente V, Vuilleumier N, Rutschmann O, Martin P, Carballo S, Saudan P. IRA acquise en communauté chez les patients avec maladie rénale chronique : une étude prospective observationnelle. Nephrol Ther 2014. [DOI: 10.1016/j.nephro.2014.07.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Guessous I, Ponte B, Marques-Vidal P, Paccaud F, Gaspoz JM, Burnier M, Waeber G, Vollenweider P, Bochud M. Clinical and Biological Determinants of Kidney Outcomes in a Population-Based Cohort Study. Kidney Blood Press Res 2014; 39:74-85. [DOI: 10.1159/000355779] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/15/2014] [Indexed: 11/19/2022] Open
|
35
|
El-Shahawy MA, Rasmussen HS, Lavin PT, Yang A, Packham DK, Singh B, Rasmussen HS, Lavin PT, Yang A, Roger SD, Fusaro M, Dalle Carbonare L, Dusso A, Arcidiacono MV, Pasho S, Gallieni M, Ormanji MS, Korkes F, Meca R, Baia LC, Ferraz RR, Heilberg IP, Roger SD, Rasmussen HS, Lavin PT, Yang A, El-Shahawy MA, Nistor I, Bararu I, Apavaloaie MC, Voroneanu L, Donciu MD, Nagler EV, Covic A, Gil HW, Park SH, Hong SY, Ponte B, Alwan H, Pruijm M, Ackermann D, Guessous I, Ehret G, Paccaud F, Mohaupt M, Pechere-Bertschi A, Burnier M, Martin PY, Bochud M, Filiopoulos V, Biblaki D, Manolios N, Karatzas I, Arvanitis D, Vlassopoulos D, Altuntas A, Kidir V, Inal S, Diker S, Cil N, Orhan H, Sezer MT, Verdelho M, Rodrigues N, Ribeiro F, Roger SD, Rasmussen HS, Lavin PT, Yang A, Qunibi WY, Azar H, Ossman R, Flamant M, Chelala D, Ria P, Fabris A, Branco C, Gambaro G, Lupo A, Hao J, Qiu L, Li Y, Li R, Li X, Chen L, Verdesca S, Cucchiari D, Podesta M, Badalamenti S, Veldhuijzen NMH, Gerritsen KGF, Boer WH, Abrahams AC, Packham DK, Rasmussen HS, Lavin PT, Yang A, Qunibi WY, Mangione F, Albrizio P, Sepe V, Esposito P, Manini A, Muciaccia S, Dal Canton A. ACID BASE, ION DISORDERS, LITHISASIS. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu150] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Gonzalez Sanchidrian S, Cebrian Andrada CJ, Jimenez Herrero MC, Deira Lorenzo JL, Labrador Gomez PJ, Marin Alvarez JP, Garcia-Bernalt Funes V, Gallego Dominguez S, Castellano Cervino I, Gomez-Martino Arroyo JR, Parapiboon W, Boonsom P, Stadler T, Raddatz A, Poppleton A, Hubner W, Fliser D, Klingele M, Rosa J, Sydor A, Krzanowski M, Chowaniec E, Sulowicz W, Vidal E, Mergulhao C, Pinheiro H, Sette L, Amorim G, Fernandes G, Valente L, Ouaddi F, Tazi I, Mabrouk K, Zamd M, El Khayat S, Medkouri G, Benghanem M, Ramdani B, Dabo G, Badaoui L, Ouled Lahcen A, Sosqi M, Marih L, Chakib A, Marhoum El Filali K, Oliveira MJC, Silva Junior G, Sampaio AM, Montenegro B, Alves MP, Henn GAL, Rocha HAL, Meneses GC, Martins AMC, Sanches TR, Andrade LC, Seguro AC, Liborio AB, Daher EF, Haase M, Robra BP, Hoffmann J, Isermann B, Henkel W, Bellomo R, Ronco C, Haase-Fielitz A, Kee YK, Kim YL, Kim EJ, Park JT, Han SH, Yoo TH, Kang SW, Choi KH, Oh HJ, Dharmendra P, Vinay M, Mohit M, Rajesh G, Dhananjai A, Pankaj B, Campos P, Pires A, Inchaustegui L, Avdoshina S, Villevalde S, Kobalava Z, Mukhopadhyay P, Das B, Mukherjee D, Mishra R, Kar M, Biswas NM, Onuigbo M, Agbasi N, Ponce D, Albino BB, Balbi AL, Klin P, Zambrano C, Gutierrez LM, Varela Falcon L, Zeppa F, Bilbao A, Klein F, Raffaele P, Chang KY, Park HS, Kim HW, Choi BS, Park CW, Yang CW, Jin DC, Checherita IA, Peride I, David C, Radulescu D, Ciocalteu A, Niculae A, Balbi A, Goes C, Buffarah M, Xavier P, Ponce D, Karimi SM, Cserep G, Gannon D, Sinnamon K, Saudan P, Alves C, De La Fuente V, Ponte B, Carballo S, Rutschmann O, Martin PY, Stucker F, Rosa J, Sydor A, Krzanowski M, Chowaniec E, Sulowicz W, Saurina A, Pardo V, Barba N, Jovell E, Pou M, Esteve V, Fulquet M, Duarte V, Ramirez De Arellano M, Sun IO, Yoon HJ, Kim JG, Lee KY, Tiranathanagul K, Sallapant S, Eiam-Ong S, Treeprasertsuk S, Peride I, Radulescu D, David C, Niculae A, Checherita IA, Geavlete B, Ciocalteu A, Ando M, Shingai N, Morito T, Ohashi K, Nitta K, Duarte DB, Silva Junior G, Vanderlei LA, Bispo RKA, Pinheiro ME, Daher EF, Ponce D, Si Nga H, Paes A, Medeiros P, Balbi A, Gentil TMS, Assis LS, Amaral AP, Alvares VRCA, Scaranello KLRS, Soeiro EMD, Castanho V, Castro I, Laranja SM, Barreto S, Molina M, Silvisk M, Pereira BJ, Izem A, Mabrouk K, Amer Mhamed D, El Khayat SS, Zamd M, Medkouri G, Benghanem M, Ramdani B, Donadio C, Klimenko A, Villevalde S, Kobalava Z, Andreoli MC, Souza NK, Ammirati AL, Matsui TN, Naka EL, Carneiro FD, Ramos AC, Lopes RK, Dias ES, Coelho MP, Afonso RC, Ferraz-Neto BH, Almeida MD, Durao M, Batista MC, Monte JC, Pereira VG, Santos OP, Santos BC, Klimenko A, Villevalde S, Kobalava Z, Silva VC, Raimann JG, Nerbass FB, Vieira MA, Dabel P, Richter A, Callegari J, Carter M, Levin NW, Winchester JF, Kotanko P, Pecoits-Filho R, Gjyzari A, Thereska N, Barbullushi M, Koroshi A, Petrela E, Mumajesi S, Kim YL, Kee YK, Han JS, Oh HJ, Park JT, Han SH, Yoo TH, Kang SW, Simone S, Scrascia G, Montemurno E, Rotunno C, Mastro F, Gesualdo L, Paparella D, Pertosa G, Lopes D, Santos C, Cunha C, Gomes AM, Coelho H, Seabra J, Qasem A, Farag S, Hamed E, Emara M, Bihery A, Pasha H, Mukhopadhyay P, Chhaya S, Mukhopadhyay G, Das C, Silva Junior G, Vieira APF, Lima LLL, Nascimento LS, Daher EF, Zawiasa A, Ko Odziejska M, Bia Asiewicz P, Nowak D, Nowicki M. CLINICAL ACUTE KIDNEY INJURY 2. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
|
37
|
Kolonko A, Chudek J, Kujawa-Szewieczek A, Czerwienska B, Wiecek A, Levin A, Madore F, Rigatto C, Barrett B, Muirhead N, Holmes DT, Clase CM, Tang M, Djurdjev O, Ponte B, Pruijm M, Ackermann D, Vuistiner P, Guessous I, Ehret G, Paccaud F, Mohaupt M, Pechere-Bertschi A, Burnier M, Martin PY, Devuyst O, Bochud M, Roussel R, Velho G, Bankir L, Balkau B, Alhenc-Gelas F, Marre M, Bouby N, Corradi V, Martino F, Gastaldon F, Scalzotto E, Nalesso F, Fortunato A, Giavarina D, Ronco C. COPEPTIN IN CKD. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Ponte B, Trombetti A, Hadaya K, Ernandez T, Fumeaux D, Iselin C, Martin PY, de Seigneux S. Acute and long term mineral metabolism adaptation in living kidney donors: a prospective study. Bone 2014; 62:36-42. [PMID: 24495507 DOI: 10.1016/j.bone.2014.01.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Revised: 01/16/2014] [Accepted: 01/28/2014] [Indexed: 01/14/2023]
Abstract
BACKGROUND Living kidney donors (LKDs) experience an abrupt decline in glomerular filtration rate (GFR). Mineral metabolism adaptations in early CKD are still debated and not well studied in LKDs. We prospectively studied acute and long term mineral metabolism adaptation of LKDs. METHODS From May 2010 to December 2012, we included 27 adult LKDs. Their mineral parameters and renal function were repeatedly measured at days 0, 1, 2, 3, 180 and 360 after donation. We also measured in uninephrectomized rats' Klotho in the remnant kidney and FGF23 circulating levels. RESULTS In the first days after nephrectomy, LKDs experience transient dilution hypocalcemia and secondary hyperparathyroidism. Urinary phosphate reabsorption decreases in spite of an abrupt decline in circulating FGF23 and Klotho. In a more chronic stage, at days 180 and 360 after donation, LKDs have lower GFR and 1,25(OH)2D compared to pre-donation levels, with unchanged 25(OH)D. PTH levels increase, resulting in decreased plasma phosphate levels and renal tubular reabsorption of phosphate. In comparison to pre-donation, FGF23 levels are not significantly changed whereas circulating Klotho levels are lower than pre-donation but higher than immediately post-donation. In uninephrectomized rats, Klotho kidney expression increases after three weeks, whereas circulating FGF23 levels are unchanged. CONCLUSION From six months after kidney donation, LKDs develop secondary hyperparathyroidism related to a decrease in 1,25(OH)2D, and decreased plasma phosphate levels. FGF23 levels do not rise in LKDs. Middle term mineral metabolism adaptations to decreased eGFR in donors include decrease in 1,25(OH)2D and increase in PTH and fractional excretion of phosphate resulting in lowered plasma phosphate levels, independently of FGF23. These adaptations differ from those described in CKD patients.
Collapse
Affiliation(s)
- B Ponte
- Service of Nephrology, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - A Trombetti
- Service of Bone Disease, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - K Hadaya
- Service of Nephrology, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - T Ernandez
- Service of Nephrology, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - D Fumeaux
- Service of Nephrology, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - C Iselin
- Service of Urology, Department of Surgery, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - P-Y Martin
- Service of Nephrology, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - S de Seigneux
- Service of Nephrology, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
| |
Collapse
|
39
|
Ponte B, Pruijm M, Ackermann D, Vuistiner P, Eisenberger U, Guessous I, Rousson V, Mohaupt MG, Alwan H, Ehret G, Pechere-Bertschi A, Paccaud F, Staessen JA, Vogt B, Burnier M, Martin PY, Bochud M. Reference Values and Factors Associated With Renal Resistive Index in a Family-Based Population Study. Hypertension 2014; 63:136-42. [DOI: 10.1161/hypertensionaha.113.02321] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Increased renal resistive index (RRI) has been recently associated with target organ damage and cardiovascular or renal outcomes in patients with hypertension and diabetes mellitus. However, reference values in the general population and information on familial aggregation are largely lacking. We determined the distribution of RRI, associated factors, and heritability in a population-based study. Families of European ancestry were randomly selected in 3 Swiss cities. Anthropometric parameters and cardiovascular risk factors were assessed. A renal Doppler ultrasound was performed, and RRI was measured in 3 segmental arteries of both kidneys. We used multilevel linear regression analysis to explore the factors associated with RRI, adjusting for center and family relationships. Sex-specific reference values for RRI were generated according to age. Heritability was estimated by variance components using the ASSOC program (SAGE software). Four hundred women (mean age±SD, 44.9±16.7 years) and 326 men (42.1±16.8 years) with normal renal ultrasound had mean RRI of 0.64±0.05 and 0.62±0.05, respectively (
P
<0.001). In multivariable analyses, RRI was positively associated with female sex, age, systolic blood pressure, and body mass index. We observed an inverse correlation with diastolic blood pressure and heart rate. Age had a nonlinear association with RRI. We found no independent association of RRI with diabetes mellitus, hypertension treatment, smoking, cholesterol levels, or estimated glomerular filtration rate. The adjusted heritability estimate was 42±8% (
P
<0.001). In a population-based sample with normal renal ultrasound, RRI normal values depend on sex, age, blood pressure, heart rate, and body mass index. The significant heritability of RRI suggests that genes influence this phenotype.
Collapse
Affiliation(s)
- Belén Ponte
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Menno Pruijm
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Daniel Ackermann
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Philippe Vuistiner
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Ute Eisenberger
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Idris Guessous
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Valentin Rousson
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Markus G. Mohaupt
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Heba Alwan
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Georg Ehret
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Antoinette Pechere-Bertschi
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Fred Paccaud
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Jan A. Staessen
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Bruno Vogt
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Michel Burnier
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Pierre-Yves Martin
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| | - Murielle Bochud
- From the Division of Nephrology (B.P., P.-Y.M.), Division of Cardiology (G.E.), Unit of Populational Epidemiology, Division of Primary Care Medicine (I.G.), and Hypertension Unit (A.P.-B.), University Hospital of Geneva, Switzerland; Institute of Social and Preventive Medicine (B.P., P.V., I.G., V.R., H.A., F.P., M.B.) and Division of Nephrology (M.P., M.B.), University Hospital of Lausanne, Lausanne, Switzerland; Department of Nephrology, Hypertension, and Clinical Pharmacology, Inselspital, Bern
| |
Collapse
|
40
|
Ponte B, Pruijm M, Marques-Vidal P, Martin PY, Burnier M, Paccaud F, Waeber G, Vollenweider P, Bochud M. Determinants and burden of chronic kidney disease in the population-based CoLaus study: a cross-sectional analysis. Nephrol Dial Transplant 2013; 28:2329-39. [PMID: 23825103 DOI: 10.1093/ndt/gft206] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Chronic kidney disease (CKD) represents an increasing health burden. We present the population-based prevalence of CKD and compare the CKD Epidemiology collaboration (CKD-EPI) and modification of diet in renal disease (MDRD) equations to estimate the glomerular filtration rate, using the revised CKD classification with three albuminuria classes. We also explore factors associated with CKD. METHODS The Swiss population-based, cross-sectional CoLaus study conducted in Lausanne (2003-2006) included 2810 men and 3111 women aged 35-75. CKD prevalence was assessed using CKD-EPI and MDRD equations and albuminuria estimated by the albumin-to-creatinine ratio in spot morning urine. Multivariate logistic regression was used to analyse determinants of CKD. RESULTS Prevalence [95% confidence interval (CI)] of all stages CKD was 10.0% (9.2-10.8%) with CKD-EPI and 13.8% (12.9-14.6%) with MDRD. Using the revised CKD classification, the prevalence of low-, medium-, high- and very high-risk groups was 90.0, 8.46, 1.18 and 0.35% with CKD-EPI, respectively. With MDRD, the corresponding values were 86.24, 11.86, 1.55 and 0.35%. Using the revised classification, CKD-EPI systematically reclassified people in a lower risk category than MDRD. Age and obesity were more strongly associated with CKD in men [odds ratio (95% CI): 2.23(1.95; 2.56) per 10 years and 3.05(2.08;4.47), respectively] than in women [1.46 (1.29; 1.65) and 1.78 (1.30;2.44), respectively]. Hypertension, type 2 diabetes, serum homocysteine and uric acid were positively independently associated with CKD in men and women. CONCLUSIONS One in 10 adults suffers from CKD in the population of Lausanne. CKD-EPI systematically reclassifies people in a lower CKD risk category than MDRD. Serum homocysteine and uric acid levels are associated with CKD independently of classical risk factors such as age, hypertension and diabetes.
Collapse
Affiliation(s)
- Belén Ponte
- Service of Nephrology, Geneva University Hospital, Geneva, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Bourquin V, Ponte B, Zellweger M, Levy M, Moll S. [Primary glomerulonephritis in focus]. Rev Med Suisse 2013; 9:764-769. [PMID: 23659154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The glomerulonephritis (GN) are responsible for a significant amount of end stage renal disease. They may be secondary to another disease or idiopathic. When a secondary etiology has been excluded, it is called primary glomerulonephritis (PGN). Glomerular damage may have different presentations and there are many way to classify them. It is thus difficult for the non-specialist to understand the terminology used. This article is a summary of the most frequently encountered PGN such as: IgA nephropathy, membranous GN, idiopathic nephrotic syndrome, extracapillary and membranoproliferative GN. A brief description is given for each one of the PGN including epidemiology, semiology, histology and a pathophysiology explanation.
Collapse
Affiliation(s)
- Vincent Bourquin
- Service de Néphrologie, Hôpital de la Tour, Avenue J.-D. Maillard 3, 1217 Meyrin.
| | | | | | | | | |
Collapse
|
42
|
Bourquin V, Ponte B, Pugin J, Martin PY, Saudan P. Use of high-volume haemodiafiltration in patients with refractory septic shock and acute kidney injury. Clin Kidney J 2012; 6:40-44. [PMID: 27818750 PMCID: PMC5094390 DOI: 10.1093/ckj/sfs166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2011] [Accepted: 10/25/2012] [Indexed: 11/12/2022] Open
Abstract
Background High-volume haemofiltration (HVHF) has been used successfully in animal models with sepsis, and preliminary data have shown that this technique may improve the haemodynamics in patients with refractory septic shock. We used high-volume continuous venovenous haemodiafiltration (CVVHDF) in patients with acute kidney injury (AKI) and refractory septic shock to evaluate their outcome when compared with their prognosis predicted by scores of severity. Methods This is a cohort study in a Medical and Surgical Intensive Care Unit. Fifty-five patients with refractory septic shock and AKI were included in the study. Results High-volume CVVHDF was started in patients with AKI and septic shock requiring norepinephrine dose >0.2 µg/kg/min. AKI was classified according to the RIFLE criteria. Treatment was implemented within the first 24 h of refractory septic shock with a dialysis dose of 70 mL/kg/h until reversal of shock or death. Fifty-five patients were treated with high-volume CVVHDF with an observed mortality of 63%, similar to the mortality predicted by the APACHE II and SAPS II scores. Conclusion Survival rate in our patients with AKI and refractory septic shock treated with high-volume CVVHDF was identical to survival predicted by the severity scores. Treatment with high-volume haemodiafiltraton is applicable to severely ill patients with septic shock but does not confer any clear advantage in terms of survival. This therapy should not be implemented on a routine basis in patients with AKI and refractory septic shock.
Collapse
Affiliation(s)
- Vincent Bourquin
- Service de Néphrologie, Département des Spécialités de Médecine , Hôpitaux Universitaires de Genève , Geneva , Switzerland
| | - Belén Ponte
- Service de Néphrologie, Département des Spécialités de Médecine , Hôpitaux Universitaires de Genève , Geneva , Switzerland
| | - Jérôme Pugin
- Service des Soins Intensifs, Département d'Anesthésiologie, de Pharmacologie et des Soins Intensifs , Hôpitaux Universitaires de Genève , Geneva , Switzerland
| | - Pierre-Yves Martin
- Service de Néphrologie, Département des Spécialités de Médecine , Hôpitaux Universitaires de Genève , Geneva , Switzerland
| | - Patrick Saudan
- Service de Néphrologie, Département des Spécialités de Médecine , Hôpitaux Universitaires de Genève , Geneva , Switzerland
| |
Collapse
|
43
|
Ponte B, Pagano S, Spahr L, Berra G, Lescuyer P, Martin PY. La cystatine c est le meilleur prédicteur précoce d’insuffisance rénale aiguë chez le patient cirrhotique. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Stucker F, Pugin J, Tataw J, Ponte B, Brochard L, Martin P, Saudan P. Efficacité et sécurité d’une anticoagulation régionale au citrate chez des patients avec insuffisance rénale aiguë aux soins intensifs. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Ponte B, Pruijm M, Ackermann D, Eisenberger U, Burnier M, Martin PY, Bochud M. Échographie rénale dans la population générale suisse : premiers résultats d’une étude multicentrique. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Michelet PR, Ponte B, Samii K, de Seigneux S, Martin PY, Hadaya K. Neutropénies sévères précoces post transplantation rénale : prédominance des causes médicamenteuses incluant le tacrolimus. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Saudan P, Marangon N, de Seigneux S, Ponte B, Stoermann C, Martinez C, Martin PY. Suivi spécialisé chez les patients avec maladie rénale chronique stade IIIb-IV : impact sur la survie et les hospitalisations en urgence ? Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
48
|
Conde E, Alegre L, Blanco-Sánchez I, Sáenz-Morales D, Aguado-Fraile E, Ponte B, Ramos E, Sáiz A, Jiménez C, Ordoñez A, López-Cabrera M, del Peso L, de Landázuri MO, Liaño F, Selgas R, Sanchez-Tomero JA, García-Bermejo ML. Hypoxia inducible factor 1-alpha (HIF-1 alpha) is induced during reperfusion after renal ischemia and is critical for proximal tubule cell survival. PLoS One 2012; 7:e33258. [PMID: 22432008 PMCID: PMC3303832 DOI: 10.1371/journal.pone.0033258] [Citation(s) in RCA: 125] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2011] [Accepted: 02/06/2012] [Indexed: 01/17/2023] Open
Abstract
Acute tubular necrosis (ATN) caused by ischemia/reperfusion (I/R) during renal transplantation delays allograft function. Identification of factors that mediate protection and/or epithelium recovery could help to improve graft outcome. We studied the expression, regulation and role of hypoxia inducible factor 1-alpha (HIF-1 α), using in vitro and in vivo experimental models of I/R as well as human post-transplant renal biopsies. We found that HIF-1 α is stabilized in proximal tubule cells during ischemia and unexpectedly in late reperfusion, when oxygen tension is normal. Both inductions lead to gene expression in vitro and in vivo. In vitro interference of HIF-1 α promoted cell death and in vivo interference exacerbated tissue damage and renal dysfunction. In pos-transplant human biopsies, HIF-1 α was expressed only in proximal tubules which exhibited normal renal structure with a significant negative correlation with ATN grade. In summary, using experimental models and human biopsies, we identified a novel HIF-1 α induction during reperfusion with a potential critical role in renal transplant.
Collapse
Affiliation(s)
- Elisa Conde
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - Laura Alegre
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
- Department of Nephrology, Instituto de Investigación La Princesa (IP), Madrid, Spain
| | - Ignacio Blanco-Sánchez
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - David Sáenz-Morales
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - Elia Aguado-Fraile
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - Belén Ponte
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - Edurne Ramos
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - Ana Sáiz
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - Carlos Jiménez
- Department of Nephrology, Hospital La Paz (IdIPaz), Madrid, Spain
| | - Angel Ordoñez
- Department of Immunology, Instituto de Investigación La Princesa (IP), Madrid, Spain
| | | | - Luis del Peso
- HIV Unit, Department of Biochemistry, Hospital La Paz (IdiPAZ), Autónoma University School of Medicine, Institute of Biomedical Research Alberto Sols, CSIC-UAM, Madrid, Spain
| | | | - Fernando Liaño
- Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain
- Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
| | - Rafael Selgas
- Department of Nephrology, Hospital La Paz (IdIPaz), Madrid, Spain
| | | | - María Laura García-Bermejo
- Department of System Disorders and Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Alcalá University, Madrid, Spain
- * E-mail:
| |
Collapse
|
49
|
Pruijm M, Ponte B, Vollenweider P, Mooser V, Paccaud F, Waeber G, Marques-Vidal P, Burnier M, Bochud M. Not all inflammatory markers are linked to kidney function: results from a population-based study. Am J Nephrol 2012; 35:288-94. [PMID: 22398717 DOI: 10.1159/000335934] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2011] [Accepted: 12/17/2011] [Indexed: 11/19/2022]
Abstract
BACKGROUND Several studies have reported increased levels of inflammatory biomarkers in chronic kidney disease (CKD), but data from the general population are sparse. In this study, we assessed levels of the inflammatory markers C-reactive protein (hsCRP), tumor necrosis factor α (TNF-α), interleukin (IL)-1β and IL-6 across all ranges of renal function. METHODS We conducted a cross-sectional study in a random sample of 6,184 Caucasian subjects aged 35-75 years in Lausanne, Switzerland. Serum levels of hsCRP, TNF-α, IL-6, and IL-1β were measured in 6,067 participants (98.1%); serum creatinine-based estimated glomerular filtration rate (eGFR(creat), CKD-EPI formula) was used to assess renal function, and albumin/creatinine ratio on spot morning urine to assess microalbuminuria (MAU). RESULTS Higher serum levels of IL-6, TNF-α and hsCRP and lower levels of IL-1β were associated with a lower renal function, CKD (eGFR(creat) <60 ml/min/1.73 m(2); n = 283), and MAU (n = 583). In multivariate linear regression analysis adjusted for age, sex, hypertension, smoking, diabetes, body mass index, lipids, antihypertensive and hypolipemic therapy, only log-transformed TNF-α remained independently associated with lower renal function (β -0.54 ±0.19). In multivariate logistic regression analysis, higher TNF-α levels were associated with CKD (OR 1.17; 95% CI 1.01-1.35), whereas higher levels of IL-6 (OR 1.09; 95% CI 1.02-1.16) and hsCRP (OR 1.21; 95% CI 1.10-1.32) were associated with MAU. CONCLUSION We did not confirm a significant association between renal function and IL-6, IL-1β and hsCRP in the general population. However, our results demonstrate a significant association between TNF-α and renal function, suggesting a potential link between inflammation and the development of CKD. These data also confirm the association between MAU and inflammation.
Collapse
Affiliation(s)
- Menno Pruijm
- Department of Nephrology, University Hospital of Lausanne, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Bourquin V, Ponte B, Zellweger M, Levy M, Hadengue A, Moll S. [Phosphate nephropathy: how to avoid it?]. Rev Med Suisse 2011; 7:2227-2231. [PMID: 22400350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Colonoscopy is a commonly used procedure for colon cancer screening. The ideal bowel preparation for a good visualization of the colonic mucosa would be effective and well tolerated. Sodium phosphate (NaP) and polyethylen glycol (PEG) are the two most frequently used solutions in this indication. However, although NaP has been described as more effective and better tolerated, it can cause severe acute electrolytes disturbances and, in rare cases, lead to irreversible renal failure, called phosphate nephropathy. NaP should therefore be prescribed with caution and be formally banned for patients with risk factors.
Collapse
|